Sweden's Bonesupport Q2 sales rise 25%, trims 2026 growth outlook

BoneSupport Holding AB

16/07/2026 07:10

Overview
Sweden orthobiologics firm's Q2 net sales rose 25% yr/yr to SEK 355.7 mln
Adjusted EPS for Q2 increased to SEK 1.24 from SEK 0.81
2026 sales growth guidance cut

Outlook
Bonesupport now expects 2026 sales growth of 33-36% at constant exchange rates vs over 35% earlier

Result Drivers
SEGMENT GROWTH - US and Europe & Rest of World segments both reported sales growth of around 25% yr/yr, contributing to overall revenue increase
HIGH GROSS MARGIN - Gross margin remained high at 90.8%, though slightly lower than prior year

Company press release: ID:nMFN6ln3qc

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
SEK 355.70 mln
SEK 365 mln (2 Analysts)
Q2 Adjusted EPS
 
SEK 1.24
 
Q2 Gross Margin
 
90.80%
 
Q2 EBIT
 
SEK 89.60 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Bonesupport Holding AB is SEK372.50, about 69.8% above its July 15 closing price of SEK219.40
The stock recently traded at 35 times the next 12-month earnings vs. a P/E of 33 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)